Geun-Woo Jin

Title: Geun-Woo Jin: Innovator in Anti-Tumor Conjugate Development

Introduction

Geun-Woo Jin is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of anti-tumor agents. His innovative work focuses on synthesizing compounds that exhibit therapeutic benefits without causing toxicity.

Latest Patents

Geun-Woo Jin holds a patent for a "Docetaxel-aconitic anhydride conjugate exhibiting anti-tumor activity without in vivo toxicity." This patent details a method for synthesizing a docetaxel-aconitic anhydride conjugate. The process involves mixing aconitic anhydride with a chlorinating reagent to create a first mixture. This mixture is then dissolved in an organic solvent, stirred, and evaporated to produce a second mixture. The second mixture is washed with an impurity remover to eliminate impurities, resulting in an aconitic anhydride chloride solution. Finally, docetaxel is mixed with this solution to produce the desired conjugate.

Career Highlights

Geun-Woo Jin is associated with Cnpharm Co. Ltd., where he continues to advance his research and development efforts. His work has been instrumental in exploring new therapeutic avenues for cancer treatment.

Collaborations

Geun-Woo Jin collaborates with Hojun Kim, contributing to the innovative research environment at Cnpharm Co. Ltd. Their partnership enhances the potential for groundbreaking discoveries in the pharmaceutical industry.

Conclusion

Geun-Woo Jin's contributions to the field of anti-tumor agents highlight his innovative spirit and dedication to improving cancer therapies. His work exemplifies the importance of research and collaboration in advancing medical science.